Related Experiment Video
Updated: May 23, 2026

07:42
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Targeting the human kinome for cancer therapy: current perspectives
1Garvan Institute of Medical Research, Australia.
Critical Reviews in Oncogenesis
|April 5, 2012
Summary
Targeted cancer therapies show promise, but new research reveals a broader range of cancer-driving kinases. Understanding the full cancer kinome is key to expanding effective treatments.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Significant advancements have been made in developing targeted therapies for specific oncogenic kinases.
- Cancer genome sequencing reveals a wider spectrum of kinases involved in cancer progression than previously understood.
Purpose of the Study:
- To provide a broad perspective on the current knowledge of the cancer kinome.
- To explore how this knowledge can be expanded and utilized for clinical benefit.
Main Methods:
- Review of recent cancer genome sequencing data.
- Integration of insights from functional genomics and mass spectrometry (MS)-based proteomics.
- Analysis of intracellular signaling networks and their response to targeted agents.
Main Results:
- Identification of a broader range of kinase oncogenes contributing to cancer.
- Elucidation of the functional roles of specific kinases in various cancers.
- Understanding the dependency of kinase roles on genetic background and their impact on signaling pathways.
Conclusions:
- The cancer kinome is more complex than initially thought, offering new therapeutic targets.
- Expanding our understanding of the cancer kinome is crucial for developing novel and effective cancer treatments.
- Functional genomics and proteomics are vital for deciphering kinase functions and guiding targeted therapy development.
Related Concept Videos
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
